The role of indoleamine 2, 3 dioxygenase in regulating host immunity to leishmania infection

Journal of Biomedical Science

Levi HC Makala¹ 

[1] Georgia Health Sciences University, Medical College of Georgia, Department of Pediatrics, Hematology/oncology Section, Augusta, Georgia 30912, USA

关键词: draining lymph node;    regulatory T cell;    plasmacytoid dendritic cell;    1-methyl-d-tryptophan;    Host Immunity;    Leishmaniasis;    Mice;    Indoleamine 2,3-dioxygenase;    Leishimania major;   

Others  :  1137638
DOI  :  10.1186/1423-0127-19-5

 received in 2011-08-26, accepted in 2012-01-09,  发布年份 2012

【 摘 要 】

Pathogen persistence in immune-competent hosts represents an immunological paradox. Increasing evidence suggests that some pathogens, such as, Leishmania major (L. major) have evolved strategies and mechanisms that actively suppress host adaptive immunity. If this notion is correct conventional vaccination therapies may be ineffective in enhancing host immunity, unless natural processes that suppress host immunity are also targeted therapeutically. The key problem is that the basis of pathogen persistence in immune-competent individuals is unknown, despite decades of intense research. This fact, coupled with poor health care and a dearth of effective treatments means that these diseases will remain a scourge on humans unless a better understanding of why the immune system tolerates such infections emerges from research. Indoleamine 2,3-dioxygenase (IDO) has been shown to act as a molecular switch regulating host responses, and IDO inhibitor drugs shown to possess potential in enhancing host immunity to established leishmania infections. It is hoped that this review will help stimulate and help generate critical new knowledge pertaining to the IDO mechanism and how to exploit it to suppress T cell mediated immunity, thus offer an innovative approach to studying the basis of chronic leishmania infection in mice.

【 授权许可】

   
2012 Makala; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Leishman WB: "On the possibility of the occurrence of trypanomiasis in India". The British Medical Journal 1903.
• [2]Donovan C: "Memoranda: On the possibility of the occurence of trypanomiasis in India.". The British Medical Journal 1903.
• [3]Ross R: "Further notes on Leishman's bodies". Ibid 1903, ii:1401.
• [4]Peters N, Sacks D: Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunolo Rev 2006, 213:159-179.
• [5]Liese J, Schleicher U, Bogdan C: The innate immune response against Leishmania parasites. Immunobiology 2008, 213:377-387.
• [6]Sharma U, Singh S: Immunobiology of leishmaniasis. Indian J Exp Biol 2009, 47:412-423.
• [7]Moll H, Rollinghoff M: Resistance to murine cutaneous leishmaniasis is mediated by TH1 cells, but disease-promoting CD41 cells are different from TH2 cells. Eur J Immunol 1990, 20:2067-2074.
• [8]Lohoff M, Sommer F, Solbach W, Rollinghoff M: Coexistence of antigen-specific TH1 and TH2 cells in genetically susceptible BALB/c mice infected with Leishmania major. Immunobiology 1989, 179:412-421.
• [9]Locksley RM, Heinzel FP, Holaday BJ, Mutha SS, Reiner SL, Sadick MD: Induction of Th1 and Th2 CD41 subsets during murine Leishmania major infection. Res Immunol 1991, 142:28. 32
• [10]Scott P: IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 1991, 147:3149-55.
• [11]Scott P, Natovitz P, Coffman RL, Pearce E, Sher A: Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988, 168:1675-84.
• [12]Holaday BJ, Sadick MD, Wang ZE, Reiner SL, Heinzel FP, Parslow TG, Locksley RM: Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th1- and Th2-like cell lines. J Immunol 1991, 147:1653-8.
• [13]Reiner SL, Locksley RM: The regulation of immunity to Leishmania major. Annu Rev Immunol 1995, 13:151-77.
• [14]Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y: Infected site-restricted Foxp31 natural regulatory T cells are specific for microbial antigens. J Exp Med 2006, 203:777-88.
• [15]Belkaid Y, Tarbell K: Regulatory T cells in the control of hostmicroorganism interactions (*). Annu Rev Immunol 2009, 27:551-89.
• [16]Belkaid Y, Tarbell KV: Arming Treg cells at the inflammatory site. Immunity 2009, 30:322-3.
• [17]Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ: Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. International Journal of Cancer 2002, 101:151-155.
• [18]Munn DH, Sharma MD, Hou D, Baban B, Lee J, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004, 114:280-290.
• [19]Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, Takikawa O, Munn DH, Gendelman HE, Persidsky Y: Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 2005, 106:2382-2390.
• [20]Munn DH, Mellor AL: Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007, 117:1147-1154.
• [21]Bogdan C, Röllinghoff M: How do Protozoan Parasites Survive inside Macrophages? Parasitology Today 1999, 15(1):22-28.
• [22]Makala LH, Baban B, Lemos H, El-Awady AR, Chandler PR, Hou DY, Munn DH, Mellor AL: Leishmania major Attenuates Host Immunity by Stimulating Local Indoleamine 2,3-Dioxygenase Expression. J Infect Dis 2011, 203:715-25.
• [23]Mellor AL, Munn DH: Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999, 20:469-473.
• [24]Sugimoto H, Oda S, Otsuki T, Hino T, Yoshida T, Shiro Y: Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 2006, 103:2611-2616.
• [25]Taylor MW, Feng GS: Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991, 5:2516-2522.
• [26]Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281:1191-1193.
• [27]Mellor AL, Munn DH: IDO expression in dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4:762-774.
• [28]Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ: Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. International Journal of Cancer 2002, 101:151-155.
• [29]Munn DH, Sharma MD, Hou D, Baban B, Lee J, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004, 114:280-290.
• [30]Potula R, Poluektova L, Knipe B, Chrastil J, Heilman D, Dou H, Takikawa O, Munn DH, Gendelman HE, Persidsky Y: Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 2005, 106:2382-2390.
• [31]Munn DH, Mellor AL: Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007, 117:1147-1154.
• [32]Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005, 22:633-642.
• [33]Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P, Mellor AL, He Y, Munn DH: Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009, 113:6102-6111.
• [34]Mellor AL, Munn DH: Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008, 8:74-80.
• [35]Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, Koni PA, Iwashima M, Munn DH: Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003, 171:1652-1655.
• [36]Mellor AL, Chandler PR, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold SP, Adams E, Munn DH: Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004, 16:1391-1401.
• [37]Baban B, Hansen AM, Chandler PR, Manlapat A, Bingaman A, Kahler DJ, Munn DH, Mellor AL: A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 2005, 17:909-919.
• [38]Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH: Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling. J Immunol 2005, 175:5601-5605.
• [39]Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB, Marshall B, Chandler P, Antonia SJ, Burgess R, Slingluff CL, Mellor AL: Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002, 297:1867-1870.
• [40]Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL: GCN2 Kinase in T Cells Mediates Proliferative Arrest and Anergy Induction in Response to Indoleamine 2,3-Dioxygenase. Immunity 2005, 22:1-10.
• [41]Guillonneau C, Mintern JD, Hubert FX, Hurt AC, Besra GS, Porcelli S, Barr IG, Doherty PC, Godfrey DI, Turner SJ: Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci USA 2009, 106:3330-3335.
• [42]Taylor MW, Feng G: Relationship between interferon-g, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB Journal 1991, 5:2516-2522.
• [43]Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y: Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med 2006, 203:777-788.
• [44]Belkaid Y, Blank RB, Suffia I: Natural regulatory T cells and parasites: a common quest for host homeostasis. Immunol Rev 2006, 212:287-300.
• [45]Bertholet S, Debrabant A, Afrin F, Caler E, Mendez S, Tabbara KS, Belkaid Y, Sacks DL: Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells. Infect Immun 2005, 73:6620-6628.
• [46]Qi H, Ji J, Wanasen N, Soong L: Enhanced replication of Leishmania amazonensis amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis. Infect Immun 2004, 72:988-995.
• [47]WHO: Programme for the surveillance and control of leishmaniasis. [http://www.who.int/emc/diseases/leish/leishmaniasis.pdf.] webcite 2001. (Internet publication)
• [48]Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL: IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009, 183:2475-2483.
• [49]Sharma MD, Baban B, Chandler PR, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007, 117:1-13.
• [50]Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY: Regulatory T cell lineage specification by the forkhead transcriptionfactor foxp3. Immunity 2005, 22:329-341.
• [51]HIV vaccine failure prompts Merck to halt trial Nature 2007, 449:390.
• [52]Robb ML: Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 2008, 372:1857-1858.
• [53]Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC: Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008, 14:617-621.
• [54]Mellor AL, Munn DH: Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 2008, 8:74-80.
• [55]Peters N, Sacks D: Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol Rev 2006, 213:159-179.
• [56]Trinchieri G: Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med 2007, 204:239-243.
• [57]Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, Sacks DL: The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001, 194:1497-1506.
• [58]Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4:762-774.
• [59]Mellor AL, Chandler P, Baban B, Hansen AM, Marshall B, Pihkala J, Waldmann H, Cobbold S, Adams E, Munn DH: Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004, 16:1391-1401.
• [60]Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, L Mellor A: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004, 114:280-290.
• [61]Baban B, Hansen AM, Chandler PR, Manlapat A, Bingaman A, Kahler DJ, Munn DH, Mellor AL: A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 2005, 17:909-919.
• [62]Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH: Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007, 67:792-801.
• [63]Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005, 11:312-319.
• [64]Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL: Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA 2008, 105:17073-17078.
• [65]Sharma MD, Baban B, Chandler P, Hou DY, Singh N, Yagita H, Azuma M, Blazar BR, Mellor AL, Munn DH: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007, 117:2570-2582.
• [66]Andersen MH: A potential role of indoleamine 2,3-dioxygenase-specific T cells in leishmania vaccination. (Comment on J Infect Dis. 2011 Mar 1;203(5):715-25). J Infect Dis 2011, 204:488-489.
• [67]No Authors: The first drug for leishmaniasis treatment. IJMR 1922, 10:492.